References
- Hillen T, Coshall C, Tilling K, et al. Cause of stroke recurrence is multifactorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke 2003;34:1457–63. [ PubMed: 12750544]
- Hankey GJ, Spiesser J, Hakimi Z, et al. Time frame and predictors of recovery from disability following recurrent ischemic stroke. Neurology 2007;68:202–5. [ PubMed: 17224574]
- Kamouchi M, Kumagai N, Okada Y, et al. Risk score for predicting recurrence in patients with ischemic stroke: the Fukuoka stroke risk score for Japanese. Cerebrovasc Dis 2012;34:351–7. [ PubMed: 23154781]
- Hsu FC, Sides EG, Mychaleckyj JC, et al. Transcobalamin 2 variant associated with poststroke homocysteine modifies recurrent stroke risk. Neurology 2011;77:1543–50. [ PubMed: 21975197]
- Sun W, Li Y, Li J, et al. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel. Platelets 2014;10:1–5. [ PubMed: 25207801]
- Hsieh YC, Seshadri S, Chung WT, et al. Association between genetic variant on chromosome 12p13 and stroke survival and recurrence: a one year prospective study in Taiwan. J Biomed Sci 2012;19:1–8. [ PubMed: 22212150]
- Arenillas JF, Massot A, Alvarez-Sabín J, et al. C-reactive protein gene C1444T polymorphism and risk of recurrent ischemic events in patients with symptomatic intracranial atherostenoses. Cerebrovasc Dis 2009;28:95–102. [ PubMed: 19494488]
- Huang X, Zhu M, Jin X, et al. Association of matrix metalloproteinase-3 serum level and the promoter 5A/6A polymorphism of the MMP-3 gene with atherosclerotic cerebral infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2008;25:653–6. [ PubMed: 19065524]
- Flex A, Gaetani E, Papaleo P, et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 2004;35:2270–5. [ PubMed: 15308783]
- Abilleira S, Bevan S, Markus HS. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J Med Genet 2006;43:897–901. [ PubMed: 16905683]
- Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41. [ PubMed: 7678184]
- Zhang W, Chen Y, Liu P, et al. Variants on chromosome 9p21.3 correlated with ANRIL expression contribute to stroke risk and recurrence in a large prospective stroke population. Stroke 2012;43:14–21. [ PubMed: 22034006]
- Wang JG, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005;45:907–13. [ PubMed: 15837826]
- Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–53. [ PubMed: 9686693]
- Dunleavey L, Beyzade S, Ye S. Rapid genotype analysis of the stromelysin gene 5A/6A polymorphism. Atherosclerosis 2000;151:587–9. [ PubMed: 10944080]
- Redfors P, Jood K, Holmegaard L, et al. Stroke subtype predicts outcome in young and middle-aged stroke sufferers. Acta Neurol Scand 2012;126:329–35. [ PubMed: 22339042]
- Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251–62. [ PubMed: 11861412]
- Munshi A, Rajeshwar K, Kaul S, et al. Association of tumor necrosis factor-α and matrix metalloproteinase-3 gene variants with stroke. Eur J Neurol 2011;18:1053–9. [ PubMed: 21219546]
- Samnegård A, Silveira A, Tornvall P, et al. Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 2006;259:530–6. [ PubMed: 16629857]
- Liu KJ, Rosenberg GA. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med 2005;39:71–80. [ PubMed: 15925279]
- Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Investig 1994;94:2493–503. [ PubMed: 7989608]
- Lien LM, Hsieh YC, Bai CH, et al. Association of blood active matrix metalloproteinase-3 with carotid plaque score from a community population in Taiwan. Atherosclerosis 2010;212:595–600. [ PubMed: 20609440]
- Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006;69:636–45. [ PubMed: 16122719]
- Ye S, Eriksson P, Hamsten A, et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996;271:13055–60. [ PubMed: 8662692]
- Zhu C, Odeberg J, Hamsten A, et al. Allele-specific MMP-3 transcription under in vivo conditions. Biochem Biophys Res Commun 2006;348:1150–6. [ PubMed: 16904077]
- Huang X, Jin X, Zhu M, et al. Correlation between matrix metalloproteinase-3 polymorphism and the stability of carotid plaque. Chin J Neurol 2009;42:233–6.